RGS10 and ovarian carcinoma: In ovarian cancer cells, RGS10 suppression increases proliferation by phosphorylation of mTOR, 4E-BP1, p70S6K, and rProtein-S6, including in the presence of chemotherapy (Altman et al., 2015), loss of RGS10 expression contributes to the development of chemoresistance (Cacan et al., 2014), and modulating RGS10 expression can alter sensitivity to paclitaxel, cisplatin, and vincristine (Cacan et al., 2014; Hooks et al., 2010; Hooks and Murph, 2015).